INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 02,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 29
METHODS OF CORRECTING THE SIDE EFFECTS OF ANTI-TUBERCULOSIS
DRUGS IN RESISTANT TUBERCULOSIS WITH POST-COVID SYNDROME
AGAINST THE BACKGROUND OF CONCOMITANT PATHOLOGIES
Tojiboyev D., Tashaliyev Sh., Aliyev E.N.
Fergana regional phthisiatry and pulmonology center
Axmedov I., Ahmadjonov A., Abdurashidov A.
Fergana Medical Institute of Public Health
Abstract:
The current situation in phthisiology in the Republic remains quite tense (especially in
connection with the increase in cases of severe course, progressive forms of tuberculosis after
suffering from COVID pneumonia) and the increasing incidence of drug-resistant tuberculosis in
this group of patients associated with the frequent use of antibiotics and chemical antimicrobial
drugs ( fluoroquinolones ) in general medical institutions.
Key words:
aplastic anemia, heart palpitations, tivortin, thiotrozolinna, levocarnitine, mildronate,
erythropoietin
INTRODUCTION
I was correcting the complex treatment, allowing to prevent the development of side effects of
anti-tuberculosis drugs in patients with tuberculosis against the background of concomitant and
competitive pathologies
We have studied the case histories of 20 patients with tuberculosis and concomitant pathologies,
treated for a broad-spectrum form of tuberculosis with concomitant pathologies of the lungs
(meaning previous viral pneumonia), heart and digestive organs. In 12 patients out of 20, against
the background of tuberculous lesions of the lungs (data from X-ray and computed tomography),
before the start of antibacterial treatment, residual changes after previous covid pneumonia were
detected (the presence of varying degrees of pneumofibrosis combined with caseous
degeneration of the lungs). In two patients out of 6 with post-covid changes in combination with
hypertension, against the background of therapy with antihypertensive drugs, the condition was
aggravated by the manifestation of dyspepsia, three patients had symptoms of anosmia. One
patient had pulmonary hemorrhage, and two elderly patients had manifestations of aplastic
anemia, the remaining patients had mild forms of dyspepsia, shortness of breath, increased heart
rate, and the appearance of symptoms of polyneuropathy [1]. The complex therapy eliminated
the side effects of the drugs by the end of the 2nd month, only in two female patients, they
persisted in the form of peripheral polyneuropathy of stages 2 and 3. Analysis of the frequency
of side effects of anti-tuberculosis drugs before the COVID pandemic period established: a
significant increase in the frequency of side effects in patients with pulmonary tuberculosis,
which is presumably associated with multi-organ changes after suffering coronavirus and
polypharmacy in the treatment of COVID.
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 02,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 30
RESULTS
Traditionally used pyridoxine hydrochloride in therapeutic doses did not give the expected effect,
in connection with this, a reduction in the Linezolid dose was undertaken from 600 mg to 300
mg, due to which the drug was retained in the standard treatment regimen. In the complex
treatment of patients for the prevention of side effects included: cardioprotectors,
hepatoprotectors, drugs improving microcirculatory clearance (with the exception of patients
with hypertension, due to the side effect of Bedaquiline, Delanamid and Clofazimine (increasing
the risk of prolongation of the QT interval). When clinical symptoms of toxic liver damage
appeared, Corsil, Essentiale, Phosphogliv were connected; these drugs were prescribed by a
hepatologist [2].
In the complex treatment of widely resistant forms of tuberculosis, drugs are used that
have a toxic effect on the heart, liver, and hematopoietic system. From this position, it is
necessary to carry out prevention of the development of side effects using new means of
pathogenetic therapy in the pharmacotherapy scheme, one of which is a solution of lesfal,
essinciale, remaxol, and glutoxim. Its use in the early stages of chemotherapy allows to stop the
manifestations of a "bacterial crisis" in observed patients with severe forms of tuberculosis in
74% (27) of patients [3]. The use of these drugs to correct the side effects of chemotherapy
allows to do without the cancellation of anti-tuberculosis drugs. Compliance with a diet also
allows to better tolerate drugs.
CONCLUSION
Thus, the use of tivortin, thiotrozolin, levocarnitine, mildronate, erythropoietin (how many
patients, what were the results) Lesfal, Essenciale, Heparixol and Glutoxim in patients with
tuberculosis receiving treatment for extensively resistant tuberculosis with concomitant liver
pathology allows to improve the quality of life of patients and, in a significant percentage of
cases, improve laboratory test results, and reduce intolerance to anti-tuberculosis drugs.
REFERENCES:
1. G. A. Baryshnikova , S.A. Chorbinskaya , TA Zimina , II Stepanova , NA Kudryavtseva
2. Tenforde M., Kim S., Lindsell C. et al. Symptom duration and risk factors for delayed return
to usual health among outpatients with COVID-19 in a multistate health care systems network
3. https://www.gov.uk/government/publications/covid-19-long-term-health-effects
